AstraZeneca Results Presentation Deck
Europe
Diverse source of
Total Revenues
EROW
H1 2023
Total Revenue
US
CEO Opening Remarks
Farxiga - - strategic development
Redefined outcomes for patients, clear evidence of AstraZeneca's core strength in CVRM
Emerging
Markets
Financial Results
Heart failure
Growth driven by HF and CKD¹
Type-2
diabetes
Oncology
Split of Farxiga
new patient share
Chronic
kidney disease
BioPharmaceuticals
Rare Disease
Others
Farxiga SGLT2i class leadership²
CEO Closing Remarks
SGLT2i share
(days of treatment)
Phased LOE with a late-stage pipeline to sustain therapy area leadership
Farxiga
1.AstraZeneca internal estimates. 2. Based on internal analysis by AstraZeneca UK Limited using data from IQVIA MIDAS® SU volume data for the period Q1 2023, covering 55 countries and reflecting estimates of real-world activity. Copyright IQVIA. All rights
21 reserved. DOT calculated based on AstraZeneca dosing assumptions
CVRM = cardiovascular, renal and metabolism; HF = heart failure; CKD = chronic kidney disease; SGLT2i = sodium/glucose cotransporter-2 inhibitor; LOE = loss of exclusivity.
4View entire presentation